Status:
COMPLETED
Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer
Lead Sponsor:
Pfizer
Conditions:
Breast Neoplasms
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
Patients with advanced breast cancer to receive sunitinib (Sutent) once daily until disease progression.
Eligibility Criteria
Inclusion
- Histologically or cytologically proven diagnosis of breast cancer
- Metastatic or locally recurrent disease that is, in the opinion of the investigator, not amenable to resection or radiation therapy
- Patients with at least one measurable lesion as per RECIST
Exclusion
- Inflammatory breast cancer
- Prior treatment with VEGF inhibitors (unless in adjuvant setting at least 12 months ago)
Key Trial Info
Start Date :
August 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2010
Estimated Enrollment :
83 Patients enrolled
Trial Details
Trial ID
NCT00471276
Start Date
August 1 2007
End Date
June 1 2010
Last Update
July 25 2011
Active Locations (31)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Bakersfield, California, United States, 93309
2
Pfizer Investigational Site
Burbank, California, United States, 91505-4866
3
Pfizer Investigational Site
Fountain Valley, California, United States, 92708
4
Pfizer Investigational Site
Hawthorne, California, United States, 90250